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Hypertension (HTN) is the most commonco-morbidity in the world, and its sequelae, heart failure (HF) is one of mostcommon
causes of mortality and morbidity in the world. Current understanding of pathophysiology and management of HTN in HF is
mainlybased on studies,which havemainlyincluded whites.Amongracial groups,African-American adults havethehighestrates
(44%) of hypertension in the world and are more resistant to treatment. There is an emerging consensus on the signiﬁcance of
racial disparities in the pathophysiology and treatment options of hypertension and heart failure. However, African Americans
had been underrepresented in all the trials until the initiation ofthe A-HEFT trial. Since the recognition of obstructive sleep apnea
(OSA) as an important medical condition, large clinical trials have shown beneﬁts of OSA treatment among patients with HTN
and HF. This paper focuses on the pathophysiology, causes of secondary hypertension, and treatment of hypertension among
African-American patients with heart failure. There is increasing need for randomized clinical trials testing innovative treatment
options for African-American patients.
1.Introduction
Hypertension (HTN) is the most common comorbidity
in the world with signiﬁcant public health implications
[1, 2]. The overall U.S. prevalence of hypertension among
adults ages ≥18 years in 2005–2008 was 30.9% and was
highest among persons ages ≥65 years (69.7%) [3] and non-
Hispanic blacks (44%) [4]. The American Heart Association
estimates that the incurred costs of hypertension are more
than $93.5billion per year, and that cardiovascular disease
and stroke for which HTN is the predominant risk factor,
account for 17% of the total annual health expenditures in
the United States [5].
Hypertension and its sequelae, heart failure (HF) [6], are
a progressive disease. Evidence shows that less than half of
patients with heart failure survive ﬁve years (after diagnosis),
and less than a quarter of them live ten years after their
initial diagnosis [7]. The incidence is about 550,000 each
year in the United States. Framingham Heart Study showed
that hypertensive patients were more likely to develop heart
failure (142 cases of HF detected during the ﬁrst 16 years
of followup) than those who were normotensive [8]. The
lifetime risk for development of HF among people with
blood pressure (BP) >160/90mmHg is double that of those
with BP <140/90mmHg. Heart failure in comparison to the
most prevalent gender malignancies (bowel cancer in men
and breast cancer in women), was associated with worse
long-term survival [9]. In addition to poor prognosis, the
socioeconomic burdenis enormous.Overa million hospital-
izations, contributing to more than 250,000 deaths [4], and
escalating billions of dollars in health care expenditure is the
norm [10].2 International Journal of Hypertension
The disastrous duo, HTN and HF, should be recognized,
and a tailored focus on management in special populations,
high-risk ethnic minority groups especially blacks who are
disproportionately burdened should be developed. Among
racial groups, African-American adults have the highest
rates (44%) of hypertension in the world [4]a n da r em o r e
resistant [11] to treatment. In particular, black women have
the highest prevalence [4] and the lowest blood pressure
control [12]. The relative incidence of HF is 50% higher
in African Americans, 3% of whom have HF, compared
with 2% of the general population [13, 14]. Incident HF
is substantially more common among black than nonblack
hypertensive patients [15]. The disease occurs at an earlier
age, and usually at a more advanced stage [10] along with
increased hospitalization [16]a n dm o r t a l i t y .
Hypertension is one of the most common causes of HF.
Other causes of HF include coronary artery disease, valvular
heart disease, diabetes, left ventricular hypertrophy and
cardiomyopathies. HF can result from systolic, diastolic or
combinedleftventriculardysfunction [17].OvertclinicalHF
resulting from diastolic left ventricular dysfunction may be
clinically indistinguishable from that resulting from systolic
dysfunction. HF with preserved left ventricular function is
observedin30%to50%ofadultcasesofHF.Coronaryartery
disease and myocardial infarction is a principal cause of sys-
tolic left ventricular dysfunction followed by hypertension.
A variety of neurohormonal systems, especially the renin-
angiotensin aldosterone and sympathetic nervous systems
are activated in response to the left ventricular dysfunction
and such activation leads to abnormal ventricular remod-
eling. The inexorable progression to more severe stages of
left ventricular dysfunction can be signiﬁcantly reduced by
eﬀective therapy with neurohormonal blockade including
Angiotensin Converting enzyme inhibitors (ACEIs), Beta
Blockers(BBs), and aldosterone antagonists [18].
1.1. Pathophysiology. Current understanding of the patho-
physiology of HF has revolved around neurohormonal acti-
vation [19, 20]. Evidence suggests that abnormal endothe-
lial function may contribute to abnormal blood pressure
responses. This endothelial dysfunction may result from
insuﬃcient nitric oxide (NO) secondary to either reduced
endothelialproductionofNO orto increase NOinactivation
[17, 19, 21]. In HF, a pronounced increase in angiotensin II,
with modestly reduced NO is seen among whites. However,
African Americans with HF may exhibit greater NO reduc-
tion; conversely, angiotensin II might be less elevated among
whites.
Important studies areinvestigating genevariation among
the races that may inﬂuence the risk of developing hyper-
tension and its complications, such as single nucleotide
polymorphisms in the genes encoding for β1-adrenergic
receptors and a2c-adrenergic receptors. African Americans
who are homozygous for polymorphisms in both the β1-
adrenergic and a2c-adrenergic receptor genes are at a 10-
fold greater risk for heart failure, which is overexpressed
in African-Americans [22]. Groups with overexpression
of transforming growth factor β-1 (TGF-β1), a cytokine
involved in cardiac ﬁbrosis and remodeling, vascular and
renal disease, production of the vasoconstrictor, endothelin-
1, and stimulation of renin release, have a worse prognosis.
OthergeneticpolymorphismsinAfricanAmericansthatmay
inﬂuence heart failure risk include elevated production of
endothelial nitric oxide synthase, aldosterone synthase, and
the G protein 825-T allele [14].
2.Management
There are two major approaches to classifying the patient’s
HF stage or clinical severity. The most common is the New
York Heart Association (NYHA) classiﬁcation, mainly based
on functional capacity and subjective level of symptoms
s e v e r i t y .T h i ss c h e m ei sﬂ u i da n di t sc l a s sﬂ u c t u a t e si n
the same patient depending on their subjective assessment
and clinical status. The other approach, adopted by the
American College of Cardiology/American Heart Associa-
tion(ACC/AHA)guidelines,emphasizes diseaseprogression.
C l a s s i ﬁ e da ss t a g e sA ,B ,C ,a n dD ,e a c ho ft h e s es t a g e sh a s
deﬁnablecharacteristics andrecommendedinterventions.To
emphasize the progressive nature of HF and the need to
prevent its development or progression to end-stage disease
(stage D) [18, 23], this scheme is unidirectional. Patients can
only progress toward worsened disease severity.
Current HF guidelines deﬁne patients in stage A as
those at increased risk for HF without evidence of structural
heart disease or symptoms of HF [18]. Stage A represents a
critically important group because many of the risk factors
including hypertension can be eﬀectively controlled and
by doing so may prevent development of cardiovascular
diseases including HF. Patients are in stage B when they
present with evidence of structural heart disease but without
current or prior symptoms of HF. Stage C is recognized
by the presence of structural heart disease and current or
prior symptoms of HF. Stage D patients are those who have
refractory heart failure requiring frequent hospitalization
and specialized interventions. They are symptomatic at rest
despite maximally tolerated medical and device therapy.
3.TreatmentofHypertensioninHeartFailure
Several studies have shown the eﬃcacy of treatment of
hypertension in preventing HF [24–27]. Treatment of hyper-
tension reduces the incidence of HF by about 50%. In recent
years, signiﬁcant advances have been made in increasing
awareness, treatment, and control of blood pressure. Several
large, randomized clinical trials have shown that speciﬁc
classes of medication have mortality beneﬁt in patients with
heart failure [28–34].
3.1. Treatment Goals. In the most recent guidelines [18]f o r
thediagnosis andmanagementofHFinadults,theAmerican
College of Cardiology Foundation (ACCF)/American Heart
Association (AHA) recognized the need for speciﬁc recom-
mendations for special population. Our review expounds on
the speciﬁc concerns in Blacks.
3.2. Lifestyle Therapy. Lifestyle modiﬁcations have been
shown to reduce blood pressure, increase drug eﬃcacy,International Journal of Hypertension 3
and decrease cardiovascular risk. Long-term primary pre-
vention of hypertension includes weight reduction in over-
weight/obese individuals. Weight loss intervention was asso-
ciatedwith a21% reductionin the incidenceofhypertension
over a 36-month period [35]. Dietary practices, reducing
intake of dietary sodium to <1.5g NaCl [3, 36], low
potassium, magnesium, and saturated fat intake, increased
calcium intake [37], decreased consumption of alcohol,
have demonstrated greater BP reduction in blacks [38].
These practices are most successful when reinforced with
comprehensive education and counseling [39, 40]. Exercise
training, regular aerobic physical activity for at least 30
minutes per day most days [41], has been shown to reduce
recurrent cardiac events in patients with LV dysfunction
fromischemic heartdisease andisrecommendedunderclose
medical supervision [42]. Culturally cognizant and sensitive
modalities should be implemented to help guide improved
compliance of therapeutic lifestyle changes (TLC) in special
populations [43, 44].
3.3. Pharmaceutical Therapy. Despite lifestyle modiﬁcations,
most patients with hypertension need pharmacologic ther-
apy for better BP control. In the United States, about 44
million patients are on antihypertensive medications [45].
Pharmacological treatment ofhypertension beforedevel-
opment of structural heart disease or symptoms of HF is
mainly based on studies looking at prevention of end-organ
damage. Speciﬁc classes of medication are recommended for
patients in stages B-D that have shown beneﬁt in reducing
mortality and number of hospitalizations. The reader should
referto the major guidelinesfor full treatment recommenda-
tions of HF in the general population [18, 23, 46].
There are multiple large trials for HF therapy including
management of HTN. However, ethnic minorities who are
at greater risk for developing HF remain underrepresented
in most clinical trials. According to a recent paper by
Mitchell et al. “Treatment of HF in African Americans—A
call to Action”, most of the available evidence is based on
limited representation of African Americans in these trials or
posthoc analysis of limited evidence [46]. These papers once
again summarize the available evidence in HF management
in African Americans and call for more therapeutic trial
focused in thesehigh-risk population.The African American
Heart Failure Trial (A-HEFT) was the ﬁrst heart failure
large trial to focus speciﬁcally on the African-American
population and evidence represented approximately 50% of
all African Americans ever studied in heart failure trials [47].
This is randomized placebo-controlled double blind study
of ﬁxed dose isosorbide dinitrate/hydralazine (ISBD/HYD)
(Figure 2).
In aneﬀort tosummarize eﬃcacyofavailabletreatments,
Psaty et al. conducted a meta-analysis of all trials through
2002 [48]. The database included 192,478 patients from
42 trials randomized to 7 treatment strategies including
placebo. Low-dose diuretics proved the most eﬀective ﬁrst-
line treatment for preventing cardiovascular disease and
mortality including HF. The ALLHAT trial showed that
diuretics are as eﬀective as calciumchannel blockersor ACEI
in preventing cardiovascular disease outcomes including HF.
The ALLHAT study also has suggested that thiazide-diuretic
therapy is useful in preventing disease progression [49].
Although, ALLHAT trials and othertrials showed diureticsis
the ﬁrst-line of antihypertensive therapy and is still the most
commonly prescribed antihypertensive medications, this is
challenged by recent studies as published in February JACC
and presented in the European Society of HTN meetings.
However, the diuretics used in the ALLHAT trials was
chlorthalidone a long acting thiazide (shown to eﬀectively
lower BP and improve survival), not really the same as
hydrochlorothiazide (HCTZ) which is the most commonly
prescribed antihypertensive thiazide at a dose of 12.5–25mg.
Messerli et al. (St Luke Roosevelt Hospital, New York, NY),
published the analysis of 18 trials on HCTZ where the
antihypertensive eﬀect of HCTZ at the dose that is most
often used—12.5 to 25mg a day—is consistently inferior
to that of most other antihypertensive drug [50]. The
other limitation of diuretics as ﬁrst line therapy in African
Americans is not only not adequate but also, has multiple
side eﬀects like DM, electrolyte abnormalities and urecemia,
to mention a few. However, there is still a role of diuretics
in combination with neurohormonal (Renin Angiotensin
Aldosterone Axis) blockade and when there is compelling
indication. According to the recent consensus statement of
the International Society on Hypertension in Blacks (ISHB),
chlorthalidone is favored than HCTZ [51]. Furthermore,
the ISHB consensus statement reinforces, patient above goal
BP (SBP/DBP—15/10) with (goal BP—< 130/80) end organ
damage (HF, LVH, Kidney disease) or without end organ
damage (goal BP—< 135/85) should be on at least on
combination pharmacotherapy [51].
Use of beta blockers (BB) as treatment for hypertension
has come under scrutiny. Lindholm et al. conducted a meta-
analysisof13trials,which included105,951patientsshowing
that atenolol did not improve outcomes in terms of stroke
and cardiovascular events [52]. In stage B CHF (NYHA class
I),deﬁnedbythepresenceofreducedleftventricularejection
fraction (LVEF) < 40 percent in otherwise asymptomatic
individuals, ACEIs and BBs are recommended. Stage C
HF patients (NYHA class II–III) manifest left ventricular
dysfunctionand overtsymptoms; intheseindividuals, ACEIs
and BBs are also indicated. Aldosteroneantagonists also may
be of value in these cases [51].
HF is an indication for the use of ACEI. Abundant
evidence exists to justify their use with all stages of HF.
Patients who are intolerant to ACEIs, ARBs may be used.
BBs are also recommended in HF because of clinical
studies demonstrating decreased morbidity and mortality,
and improvement in HF symptoms. The reduction of BP
with BBs may be very marginal. Aldosterone antagonists
may provide additional beneﬁt in patients with severe left
ventricular dysfunction, usually late stage C (NYHA class
III–IV). In the Randomized Aldactone Evaluation Study
(RALES),low-dose spironolactone (12.5–25mg daily), when
added tostandard therapy, decreased mortality by 34percent
[34]. In the Eplerenone Postacute Myocardial Infarction
Heart Failure Eﬃcacy and Survival Study (EPHESUS),
eplerenone reduced mortality by 15% in patients following
a recent MI with LVEF < 40%, 90% of whom had HF4 International Journal of Hypertension
symptoms [53]. Patients were excluded who had a serum
creatinine of <2.5mg/dL and hyperkalemia.
The V-HEFT I and II are a large-scale trial thatcompared
diﬀerent vasodilators with placebo and among themselves
[25]. V-HEFT I showed, the mortality rate was signiﬁcantly
lower forthe total cohort (African Americans and Whites) in
ISDN/HYD arm compared to patients treated with Prazosin
or placebo added to digitalis and diuretics (Figure 1)[ 54].
In V-HEFT II, though ISBD/HYD was statistically infe-
rior to enalapril in eﬀect on mortality, patients taking
ISBD/HYD experienced similar mortality rate in patients
taking ISBD/HYD in V-HEFT-II as those in V-HEFT-I
taking ISBD/HYD. Posthoc analysis of V-HEFT I showed
ISBD/HYD signiﬁcantly reduced mortality in African Amer-
ican patients but not in white patients. The reanalysis of V-
HEFT II, demonstrated the annual mortality rate African
American (12.9) patients receiving ISBD/HYD was 12.9%
compared with 12.8% for African Americans receiving
enalapril. Due to diﬀerence in outcomes in African Amer-
icans in V-HEFT, the African American Heart Failure Trial
(A-HEFT) deﬁnitive study was designed. The A-HEFT was
terminated earlier than anticipated completion date due to a
signiﬁcant (43%)reductionin mortality inpatientsreceiving
combination (ISDN/HYD) compared to the placebo arm
[44].
Adding the combination of a ﬁxed-dose of ISDN/HYD
(20mg/37.5mg) to a standard medical regimen for HF ,
including ACEI and BBs, is recommended in order to
improve outcomes for patients self-described as African
Americans, with NYHA functional class III or IV CHF [47].
Furthermore, genomic evidence from the GRAHF (Genetic
Risk Assessment of Heart Failure in African Americans)
arm of the African American Heart Failure Trial (A-HEFT)
showed that blacks with the more common TT phenotype
(61%) of the aldosterone synthase gene (CYP11B2) showed
greater responsiveness to the combination of isosorbide
dinitrate and hydralazine [55].
3.4. Secondary HTN. The vast majority of blacks will
have no identiﬁed cause for their HTN [56]. Past studies
elucidating the pathophysiological mechanisms have shown
conﬂicting information and further investigations exploring
the complex relationships and interactions are warranted
[57]. There are, however, several secondary forms of HTN
in blacks that are prominent and preventable. We will focus
on the most common, preventable and treatable secondary
form of hypertension, obstructive sleep apnea (OSA) [58].
3.5. Obstructive Sleep Apnea. T h ep r e v a l e n c eo fO S Ai n
hypertensive populations is estimated to range between
(30–40%) [59] and in heart failure at 53%; apnea-hypopnea
index (AHI) ≥10/h) [60]. OSA is more common in blacks
than whites [61, 62]. It is an independent risk factor for
HTN [63], nondipping of blood pressure and increased BP
variability [64] and follows a dose-dependent relationship
[65]. Aprospective study showed thatthe oddsofdeveloping
hypertension over 4–8 years was 2.89 times more likely for
participants who had AHI ≥ 15/h compared to AHI ≥ 0,
independent of known confounders [66]. Cross-sectional
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Figure 1: Higher rates of hypertension-based heart failure among
African American patients compared to white patients in heart fail-
ure trials. V-HEFT: VasodilatorHeart Failure Trial; SOLVD: Studies
ofLeftVentricularDysfunction;USCarvedilol:USCarvedilolHeart
Failure Trial; BEST: β-Blocker Evaluation of Survival Trial; MERIT-
heart failure: Metoprolol CR/XL Randomized Intervention Trial in
Congestive Heart Failure [14].
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Figure 2: A-HEFT % of black participants in diﬀerent intervention
arms [14].
data has shown 2.38-times increased likelihood of having
heart failure in association with OSA, independent of
confounders (n = 6424) [67, 68].
OSA has been shown to act through various mecha-
nisms, independent of blood pressure, in promoting left-
ventricular (LV) hypertrophy, diastolic [69], and systolic
[70] dysfunction, and overt heart failure [71]. These mech-
anisms include the hemodynamic consequences of repetitive
increases in left-ventricular transmutable wall pressure and
over time impaired vigil heart rate modulation leading to LV
hypertrophy and ventricular remodeling [58]. Additionally,
OSApatients without overt heart failure have more impaired
diastolic relaxation than those without OSA [72]. EmergingInternational Journal of Hypertension 5
evidence illustrates patients with OSA have more active
atheroscleroticdisease with agreater degreeof vessel involve-
ment and more vulnerable plaques than do patients without
the disease, resulting in greater cardiovascular burden [73].
The deﬁnite treatment for OSA, long-term adherence to
Continuous Positive Airway Pressure (CPAP) therapy, has
shown to suppress sympathetic activity [74], lower blood
pressure [75], reduce right ventricular volume [76], and
improve systolic function in patients with HF [77]. System-
aticreviews, meta-analyses, and randomized controlledtrials
have shown statistically signiﬁcant net reduction in blood
pressure with CPAP, especially in patients with increased
AHI events [78–83]. A recent 3-year study (n = 340) by
Dur´ an-Cantolla et al. reported that participants assigned to
CPAP therapy for 3 months had mean 24-hour ambulatory
blood pressure decreased by 2.1mmHg (0.4 to 3.7) mmHg
(P = .01) for systolic and 1.3 (0.2 to 2.3) mmHg (P = .02)
for diastolic blood pressures [84]. Similar evidence from
randomized trials showed up to 9% increase in LVEF [77]
and increased quality of life (QOL) and functional capacity
among patients treated with 1–3 months of CPAP therapy
[85]. Furthermore, among patients with no overt failure,
CPAP therapy has been shown to reverse impaired diastolic
relaxation [71]. There is a need for further randomized
clinical trials with CPAP therapy among high-risk ethnic
minorities especially blacks to assess whether treatment of
OSA has similar long-term eﬀects and to evaluate the eﬀect
on HTN and HF morbidity and mortality.
4.Recommendations
Taking into consideration, lifestyle and pharmaceutical
interventions, our changing health care community needs
to emphasize the essential nature of the patient-provider
relationship and establish trust and collaboration. In the
past, this has beenaccomplished through physician, patients,
family member, and other caretaker awareness, increased
education of both provider and patients, and establishment
ofcommunity outreach programs [86]. These measures have
contributed to an increase in compliance and a reduction
in the risk of hospitalizations [23, 87]. We recommend
an additional emphasis on the implementation of specialty
care in patients with heart failure in collaboration with the
primary care provider.
5.Summary
The dramatic improvement in the management of HF and
hypertension over the last 50 years has allowed us to start to
target speciﬁc populations and provide more evidence-based
treatment that will lead to an improvement in mortality
[88]. There are disparities in the prevalence, treatment, and
control of hypertension and the incidence and morbidity
and mortality of heart failure between blacks, a diverse and
heterogeneous population, and whites. The management
team needs to take into consideration new evidence and
develop tailored strategies for eﬀective treatment, especially
for hypertension, one of the main causes of HF and many
other cardiovascular complications in African Africans.
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